Dear Dr. Schulteis:

Please refer to your supplemental new drug applications (sNDAs), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for the following:

<table>
<thead>
<tr>
<th>Application</th>
<th>Product Name</th>
<th>Submitted on:</th>
<th>Received on:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 210365/S-005</td>
<td>Epidiolex (cannabidiol) 100 mg/mL oral solution</td>
<td>January 31, 2020</td>
<td>January 31, 2020</td>
</tr>
<tr>
<td></td>
<td><strong>This supplement proposes:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To support addition of treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older to the Prescribing Information.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 210365/S-006</td>
<td>Epidiolex (cannabidiol) 100 mg/mL oral solution</td>
<td>January 31, 2020</td>
<td>January 31, 2020</td>
</tr>
<tr>
<td></td>
<td><strong>This supplement proposes:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To extend the indications for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome down to patients 1 year of age and older.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 210365/S-007</td>
<td>Epidiolex (cannabidiol) 100 mg/mL oral solution</td>
<td>April 6, 2020</td>
<td>April 6, 2020</td>
</tr>
<tr>
<td></td>
<td><strong>This supplement proposes:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To update final Prescribing Information and Medication Guide, Instructions for Use, Carton, and Bottle/Container labels to indicate that Epidiolex (cannabidiol) is no longer a controlled substance.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reference ID: 4850387
APPROVAL & LABELING

We have completed our review of these applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. If the content of labeling in SPL format initially submitted with this CBE-0 labeling supplement is identical to the attached approved labeling, an additional submission of content of labeling in SPL format is not required.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on April 6, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
Approval of this submission by FDA is not required before the labeling is used.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Stephanie N. Parncutt, M.H.A., Senior Regulatory Health Project Manager, at (301) 796-4098 or Stephanie.Parncutt@fda.hhs.gov.

Sincerely,

[See appended electronic signature page]

Nick Kozauer, MD
Acting Director
Division of Neurology 2
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling
  - Prescribing Information
  - Medication Guide
  - Instructions for Use

³ For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
⁴ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
⁵ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

Nicholas A Kozauer
07/31/2020 08:00:05 PM